Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 2/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.35 |
| ▸ | SGPL1 | O95470 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL908142 | 1.00 | SYK (0.37) | SYKEGLN2MAP3K12PIK3CDPIK3R1 | |
| SCHEMBL908337 | 0.93 | GRM2 (0.37) | EGLN2MAP3K12SMOCXCR3SGPL1 | |
| SCHEMBL908015 | 0.93 | GRM2 (0.37) | EGLN2MAP3K12SMOCXCR3SGPL1 | |
| SCHEMBL907814 | 0.93 | MAP3K12 (0.37) | SYKEGLN2MAP3K12CXCR3 | |
| SCHEMBL908056 | 0.90 | SYK (0.38) | SYKMAP3K12SMO | |
| SCHEMBL908055 | 0.90 | SYK (0.38) | SYKMAP3K12SMO | |
| SCHEMBL908953 | 0.90 | SYK (0.38) | SYKMAP3K12SMO | |
| SCHEMBL908036 | 0.89 | EGLN2 (0.44) | SYKEGLN2MAP3K12PIK3CDPIK3R1 | |
| SCHEMBL908038 | 0.89 | EGLN2 (0.44) | SYKEGLN2MAP3K12PIK3CDPIK3R1 | |
| SCHEMBL907937 | 0.87 | KHK (0.41) | SYKMAP3K12SMOCXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786800-B1 | 1,4-Diarylpiperazine derivatives as capsaicin receptor modulators for treating pain | NEUROGEN CORP (US) | 2017-01-04 | — | — | EP | claimed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | claimed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | claimed |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2006-06-08 | — | — | US | claimed |
| EP-1786800-B1 | 1,4-Diarylpiperazine derivatives as capsaicin receptor modulators for treating pain | NEUROGEN CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | GPR88, PIGO, PRLHR | SYK 2213/4885EGLN2 474/4885MAP3K12 2358/4885 |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | GPR88, PRLHR, GPR68 | SYK 2295/4885EGLN2 474/4885MAP3K12 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.